GlassScriptPhysician profile
Brooks Kuhn
NPI 1851528947
$187,962.60
in general payments reported to CMS, 2019-2025
20 companies · $43K in 2025
The $43K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,001 · 2020: $2,989 · 2021: $26K · 2022: $11K · 2023: $39K · 2024: $58K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85K · Consulting Fee: $44K · Travel and Lodging: $8,445 · Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,719.33 |
| Consulting Fee | $43,527.50 |
| Travel and Lodging | $8,444.78 |
| Food and Beverage | $2,310.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $64,429.50 | 2021-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $53,281.62 | 2022-2025 | Dupixent |
| Genzyme Corporation | $21,561.29 | 2022-2025 | |
| Grifols USA, LLC | $16,841.06 | 2019-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $9,128.15 | 2021-2025 | Breztri, Fasenra, Tezspire |
| Mylan INC. | $4,704.44 | 2021-2024 | Yupelri |
| Regeneron Pharmaceuticals, INC. | $4,530.00 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,874.29 | 2019-2022 | |
| Mylan Specialty L.P. | $2,068.17 | 2019-2020 | |
| Viatris Specialty LLC | $2,022.00 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $2,003.06 | 2020-2024 | Nucala |
| Verona Pharma, INC. | $1,500.00 | 2025 | Ohtuvayre |
| Electromed, INC. | $1,200.00 | 2024 | Smartvest |
| Hill-Rom Company, INC | $875.00 | 2021 | |
| Grifols Shared Services North America, INC. | $660.00 | 2023 | Prolastin-C Liquid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $124.90 | 2025 | Pulmozyme, Esbriet, Xolair |
| Pulmonx Corporation | $89.12 | 2019 | |
| La Jolla Pharmaceutical Company | $57.30 | 2022 | |
| Merck Sharp & Dohme LLC | $12.70 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Kuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.